C2CBUSINESS.COM

C2C BUSINESS STRATEGIES LLC

Financial Research & Publications Group

Specializing in Comprehensive Financial Reports for Public and Private Lower Middle Market Companies

Strategic Risk & Opportunity Assessment Report

Predictive Oncology Inc. (NASDAQ: POAI)

Prepared by:
C2C Business Strategies LLC
Date: July 2025

Safe Harbor Statement
The business reviews presented by C2C Business Strategies, LLC may contain forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements.

Disclaimer
This business review is **NOT** a solicitation to buy or sell any security. It is provided solely for informational purposes. The content reflects facts, views, opinions, and recommendations from individuals and organizations both related and unrelated to C2C Business Strategies, LLC. C2C Business Strategies LLC does not guarantee the accuracy, completeness, or timeliness of any information presented, nor does it endorse any views, opinions, or recommendations contained herein, or provide investment advice.

C2C Business Strategies, LLC's mission is to provide and disseminate useful information on small public & private companies through business reviews and summaries. This information is intended for educational and informational purposes only and should not be construed as investment advice or an endorsement of any company discussed.

C2C Business Strategies LLC has not received compensation for this business review and does not anticipate any such compensation from the subject company or its affiliates. The business review is made available to the public via C2C Business Strategies, LLC's electronic distribution.

.
Investment Risk Notice:
Investments in small-cap companies involve a high degree of risk, which can vary significantly

1370 NC 24-87 STE 153 - CAMERON, NC 28326

919.694.7028 - INFO@C2CPIC.COM - C2CBUSINESS.COM

1. Executive Summary

This report provides a comprehensive analysis of Predictive Oncology (PAOI), an artificial intelligence (AI)-driven company dedicated to advancing precision and personalized medicine for cancer patients. PAOI leverages proprietary AI/machine learning platforms, a vast biobank of tumor samples, and advanced 3D tumor models to accelerate drug discovery and improve the success rate of drug development. The company's strategic corporate development includes historical acquisitions of key subsidiaries like Helomics, TumorGenesis Inc., and Soluble Biotech Inc., which collectively form a synergistic ecosystem for oncology drug development. Notably, PAOI recently divested its Skyline Medical Inc. subsidiary to streamline its focus on core oncology initiatives. Furthermore, a proposed merger with Renovaro Biosciences Inc. was unilaterally terminated by PAOI, highlighting the dynamic nature of its corporate landscape. This report details PAOI's core business, its technological pillars, and its significant corporate actions, providing a clear overview of its current operational scope and strategic direction within the oncology sector.

2. Company Overview

Predictive Oncology (PAOI) is an artificial intelligence (AI)-driven company focused on oncology and drug discovery. Its central mission is to accelerate precision and personalized medicine for cancer patients worldwide.[1] The company integrates scientific rigor with machine learning to overcome challenges prevalent in clinical trials and to improve the probability of success in drug development.[1] PAOI's operations are built upon several key technological pillars, strategically designed to address the high failure rates observed in traditional oncology drug development. The company's focus on "bringing the human element earlier" into drug development directly responds to the limitations of conventional models that often lead to clinical trial failures due to a lack of efficacy.[1]

Predictive Oncology is headquartered in Pittsburgh, PA.[4] Its stock is listed on the Nasdaq Capital Market under the ticker symbol POAI.[6]

Key Company Information

Attribute	Detail
Legal Name	Predictive Oncology Inc. [6]
Headquarters	Pittsburgh, PA [4]
Website	predictive-oncology.com [1]
Ticker	POAI (NASDAQ Capital Market) [6]
Industry	AI-driven oncology and drug discovery [1]
Business Model	Applying AI to personalized medicine and drug discovery to advance molecules to medicine [1]
Geographic Reach	U.S. and Europe (for ChemoFx® expansion) [7]

3. Leadership and Founding Team

Information regarding the specific leadership and founding team members, including their detailed roles and tenure, is not available in the provided research material in a format consistent with the reference report. The company's official website mentions "Leadership Team and Board of Directors" but does not provide individual names or biographies.[8]

4. Product/Service Portfolio

Predictive Oncology (PAOI) offers a comprehensive suite of solutions for the biopharma industry, integrating scientific rigor with machine learning to advance molecules into medicine more confidently.[8]

4.1. Core Technologies and Platforms

- **AI/Machine Learning Platform (PeDAL):** The company leverages proprietary AI/ML platforms, such as PeDAL, to make high-confidence drug-response predictions. This technology has been scientifically validated to predict with up to 92% accuracy whether a tumor sample will respond to a specific drug compound, enabling a more informed selection of drug/tumor type combinations for subsequent *in vitro* testing.[1] This powerful predictive engine is made possible by the extensive tumor features contained within its biobank.[1]
- **Biobank:** Predictive Oncology maintains what is described as the world's largest privately held biobank of tumor samples, comprising over 150,000 samples, complemented by 200,000 pathology slides and decades of longitudinal drug response data.[1] This extensive collection allows for deep insights into patient heterogeneity and efficiently addresses tumor heterogeneity in drug efficacy predictions.[1]
- **3D Tumor Models:** The company utilizes advanced 3D tumor models that are designed to mimic the complex human organ microenvironment. These models provide a more clinically relevant testing platform than commonly used alternatives, exhibiting a high correlation with clinical response.[1]

4.2. Products and Services

The services and applications offered by PAOI are diverse, reflecting its integrated approach to oncology drug development:

- **Drug Discovery and Repurposing:** The company's platforms optimize early drug discovery efforts and enable more efficient drug repurposing by identifying effective drug-tumor pairings.[1]
- **Clinical Testing and Research Services:** PAOI provides advanced tumor

drug-response testing and genomic biomarker profiling services, which assist in individualizing treatment plans for improved patient outcomes.[1] The company collaborates with biopharma partners, offering services that advance molecules to medicine with confidence and accuracy.[1]

- **ChemoFx® Assay:** A proprietary live-cell tumor profiling assay, ChemoFx® uses a patient's own cells to measure chemotherapy responses *in vitro*, providing personalized guidance for treatment selection. PAOI is actively preparing for aggressive market expansion of ChemoFx® in both the U.S. and Europe. This assay was a primary method through which the company acquired its extensive biobank.[7] The continued development and expansion of the ChemoFx® assay further solidifies PAOI's clinical application capabilities and its strategy for augmenting its biobank.

5. Market Position & Peer Analysis

Detailed information on Predictive Oncology's specific market share dominance, global market size within its niche, or a direct peer analysis with specific competitors' market positions is not available in the provided research material. The company operates in the rapidly growing field of AI-driven oncology and drug discovery.[4]

6. Financial Performance, Valuation & Benchmarking

Specific financial performance metrics (e.g., net sales, net income, Adjusted EBITDA, cash flow from operations) and valuation data (e.g., market capitalization, P/E ratio, EV/EBITDA) for Predictive Oncology are not available in the provided research material in a format consistent with the reference report. The latest 10-Q filing was on May 14, 2025.[5]

7. Mergers & Acquisitions (M&A) and Transactional Activity

Predictive Oncology (NASDAQ: POAI) has evolved its corporate structure through strategic acquisitions and divestitures, maintaining a focus on its core mission of

AI-driven oncology and drug discovery.[10]

7.1. Historical Acquisitions and Current Wholly-Owned Subsidiaries

PAOI has operated through various segments and currently includes several wholly-owned subsidiaries:

- **Helomics:** Acquired by Predictive Oncology through a merger agreement signed on October 26, 2018, and completed in 2019.[13] Helomics applies AI to rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. It operates a CLIA-certified lab, providing clinical testing services that assist oncologists in individualizing patient treatment decisions.[1] Helomics has a particular focus on ovarian cancer.[12]
- **TumorGenesis Inc.:** This wholly-owned subsidiary specializes in media that facilitates the growth of cancer cells while retaining their DNA/RNA and proteomic signatures. This provides researchers with a vital tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. TumorGenesis is also implementing Good Manufacturing Practice (GMP) operations for the production of its cancer cell media.[10] Its focus includes ovarian and breast cancer cells.[11]
- **Soluble Biotech Inc.:** Acquired by Predictive Oncology on June 2, 2020, along with BioDtech.[12] Soluble Biotech employs a proprietary technology to rapidly develop soluble and stable formulations for proteins, including vaccines, antibodies, and other therapeutics. The company has a GMP facility, offering manufacturing capabilities for Phase 1 clinical trials, and sells protein solubilization kits.[16]

The combination of Helomics, TumorGenesis, and Soluble Biotech within Predictive Oncology's portfolio creates a synergistic ecosystem. Helomics provides the AI-driven clinical data and expertise, TumorGenesis facilitates the development of relevant *in vitro* models, and Soluble Biotech addresses the critical challenge of drug formulation stability. This integrated capability suggests a deliberate strategy by PAOI to build a comprehensive platform covering multiple stages of oncology drug discovery and development, from initial screening to pre-clinical manufacturing. This means PAOI is positioned not merely as an "AI company" or a "biobank company," but as a holistic solution provider for biopharma partners. Any report that fails to acknowledge these distinct yet complementary roles of its subsidiaries would misrepresent PAOI's full scope and its strategic intent to offer an "end-to-end solution".[18]

Table 1: Predictive Oncology (PAOI) Key Subsidiaries and Their Status

This table provides a clear reference for PAOI's subsidiaries, their primary functions, and their current status.

Subsidiary Name	Primary Function	Acquisition Date (if applicable)	Current Status (as of July 2025)	Relevant Snippets
Helomics	AI-driven precision medicine, clinical testing, CRO services for oncology, biobank management	Acquired 2019 [13]	Wholly-owned subsidiary	[13]
TumorGenesis Inc.	Cancer cell culture media, tools for growing and studying tumor cells in lab	Wholly-owned [10]	Wholly-owned subsidiary	[10]
Soluble Biotech Inc.	Protein formulation development (solubility and stability), GMP manufacturing for Phase 1 clinical trials	Acquired 2020 [12]	Wholly-owned subsidiary	[12]
Skyline Medical Inc.	Automated medical waste fluid management system (STREAMWAY System)	Wholly-owned [10]	**Divested** to DeRoyal Industries on March 14, 2025 [19]	[19]

7.2. Divestitures: The Case of Skyline Medical

Skyline Medical Inc. was formerly a wholly-owned subsidiary of Predictive Oncology, operating within its Eagan reportable operating segment. The subsidiary's primary offering was the STREAMWAY System, a patented and FDA-cleared technology designed to automate the collection, measurement, and disposal of waste fluid in medical facilities.[20]

On March 14, 2025, Predictive Oncology entered into an asset purchase agreement with DeRoyal Industries, Inc., for the sale of the assets associated with Skyline Medical Inc. The transaction was subsequently closed on March 20, 2025.[19] Consequently, Skyline Medical is no longer a part of Predictive Oncology's corporate structure or operations.

DeRoyal Industries, Inc., the acquiring entity, is a medical device manufacturer established in 1973. Its extensive portfolio includes surgical devices, wound care products, orthopedic supports and bracing, and inventory management solutions.[21] DeRoyal Industries has a history of strategic acquisitions, with Skyline Medical being a recent addition to its portfolio.[21]

The divestiture of Skyline Medical indicates a strategic decision by Predictive Oncology to streamline its corporate portfolio and intensify its focus on core competencies. While Skyline Medical's operations were within the medical sector, they were not directly aligned with PAOI's primary business of AI-driven oncology drug discovery and development. This move allows PAOI to allocate resources more effectively towards its specialized cancer-focused initiatives. This action clarifies PAOI's current market position as a specialized oncology company.

7.3. Terminated Mergers: The Proposed Renovaro Biosciences Merger

A significant proposed corporate action that did not materialize was the merger between Predictive Oncology and Renovaro Biosciences Inc. (NASDAQ: RENB).

On January 6, 2025, Predictive Oncology announced that it had entered into a binding Letter of Intent (LOI) to be acquired by Renovaro, Inc. in an all-stock transaction.[23] The stated objective of this proposed combination was to merge their respective AI and machine learning platforms, leveraging PAOI's extensive biobank, to enhance cancer patient outcomes through improved early diagnosis, biomarker identification, and targeted therapies.[23] Renovaro's business encompasses advanced cell-gene

immunotherapy (RenovaroBio) and an AI platform for early cancer detection (Renovaro Cube).[26] Additionally, Renovaro had acquired BioSymetrics, a drug discovery company that integrates clinical and experimental data using machine learning.[28]

By March 3, 2025, both companies issued press releases indicating progress towards finalizing the definitive merger agreement. Renovaro announced it had completed the first tranche of financing to initiate integration efforts of the AI/ML platform technologies and core laboratory capabilities.[4] Public market activity and news reports at the time suggested the merger was "almost complete" by March 25, 2025.[5]

However, a critical development occurred on April 3, 2025, when Predictive Oncology (POI) sent an email unilaterally terminating the merger transaction with Renovaro Biosciences.[20] Renovaro views this termination as a breach of binding obligations and has publicly stated its intention to pursue legal remedies to recover damages, including an expedited trial for a lawsuit to enforce the binding merger agreement.[20]

Therefore, the merger between Predictive Oncology and Renovaro Biosciences *has not been completed*. Despite earlier announcements of progress and initial financing, PAOI unilaterally terminated the agreement. The relationship between PAOI and Renovaro is currently contentious, marked by ongoing legal action.[20] Any reference to Predictive Oncology as being merged with, or part of, Renovaro Biosciences (or its subsidiaries like RenovaroBio, Renovaro Cube, or BioSymetrics) is incorrect. These entities are distinct, and their planned combination did not materialize.

Table 2: Key Corporate Actions Affecting PAOI's Identity (Chronological)

This table provides a chronological overview of significant corporate actions that have shaped PAOI's identity, with a clear indication of their definitive status.

Date	Corporate Action	Entities Involved	Impact on PAOI's Identity	Current Status (as of July 2025)	Relevant Snippets
Oct 26, 2018	Merger Agreement Signed	Predictive Oncology, Helomics	Helomics to become wholly-owned subsidiary of PAOI.	**Completed** (Helomics is a wholly-owned subsidiary)	13
Jun 02, 2020	Acquisition Completed	Predictive Oncology,	Soluble Biotech &	**Completed** (Soluble	12

		Soluble Therapeutics (Soluble Biotech) & BioDtech	BioDtech become wholly-owned subsidiaries of PAOI.	Biotech is a wholly-owned subsidiary)	
Jan 06, 2025	Binding LOI for Merger	Predictive Oncology, Renovaro Biosciences	Proposed acquisition of PAOI by Renovaro.	**Terminated** by PAOI on April 3, 2025.	23
Mar 03, 2025	Merger Finalization Update & First Tranche Financing	Predictive Oncology, Renovaro Biosciences	Public announcement of progress towards definitive agreement.	**Terminated** by PAOI on April 3, 2025.	4
Mar 14, 2025	Asset Purchase Agreement Signed	Predictive Oncology, DeRoyal Industries (for Skyline Medical assets)	Divestiture of Skyline Medical assets from PAOI.	**Completed** (Skyline Medical assets are now part of DeRoyal Industries)	19
Apr 03, 2025	Merger Termination by PAOI	Predictive Oncology, Renovaro Biosciences	PAOI terminates merger agreement; Renovaro pursues legal remedies.	**Terminated** (Merger did not occur; legal dispute ongoing)	20

8. SWOT Analysis

A comprehensive SWOT analysis of Predictive Oncology (PAOI) reveals its strong internal capabilities and market position, alongside external opportunities for growth and inherent industry threats.

Strengths

- **Proprietary AI/ML Platform (PeDAL):** PAOI's core strength lies in its scientifically validated AI/ML platform, PeDAL, which can predict tumor-drug responses with up to 92% accuracy. This capability significantly optimizes early drug discovery and increases the probability of success in drug development by enabling more informed selection of drug/tumor type combinations.[1]
- **World's Largest Privately Held Biobank:** The company possesses an extensive biobank of over 150,000 tumor samples and 200,000 pathology slides, coupled with decades of longitudinal drug response data. This vast and diverse collection allows for deep insights into patient heterogeneity and efficiently addresses tumor heterogeneity in drug efficacy predictions, providing a unique data asset for its AI platform.[1]
- **Advanced 3D Tumor Models:** PAOI utilizes sophisticated 3D tumor models that mimic the complex human organ microenvironment, offering a more clinically relevant testing platform with high correlation to clinical response compared to traditional 2D models. This "human element" is introduced earlier in the drug development process.[1]
- **Integrated Solution Provider:** Through its wholly-owned subsidiaries (Helomics, TumorGenesis, Soluble Biotech), PAOI offers an end-to-end solution covering various stages of oncology drug development, from AI-driven clinical data and expertise to specialized cell culture media and protein formulation capabilities, complemented by CLIA-certified labs and GMP facilities.[1]
- **ChemoFx® Assay:** This proprietary live-cell tumor profiling assay provides personalized guidance for treatment selection by measuring chemotherapy responses *in vitro*. Its aggressive market expansion plans in the U.S. and Europe, and its role in augmenting the biobank, represent a significant growth avenue.[7]

Weaknesses

- **Reliance on Complex Technology:** While a strength, the heavy reliance on advanced AI/ML and complex biological models means that any technical limitations, data quality issues, or unforeseen challenges in these platforms could impact the company's core value proposition.
- **Capital Intensive R&D:** Drug discovery and development, even with AI

acceleration, remain capital-intensive endeavors, requiring sustained investment in research, development, and clinical validation.

- **Market Adoption Challenges:** Despite the potential of its technologies, widespread adoption by biopharma partners and clinicians requires continuous education, demonstration of value, and overcoming inertia from traditional methods.
- **Legal Dispute with Renovaro:** The ongoing legal dispute following the unilateral termination of the merger agreement with Renovaro Biosciences introduces uncertainty and potential financial and reputational costs.[20]

Opportunities

- **Growing AI in Drug Discovery Market:** The increasing integration of AI and machine learning in drug discovery presents a significant growth opportunity, as these technologies can accelerate processes and improve success rates. PAOI is well-positioned to capture a larger share of this expanding market.[1]
- **Expansion of Precision and Personalized Medicine:** The global shift towards personalized cancer therapies creates a strong demand for PAOI's tumor drug-response testing and genomic biomarker profiling services, which individualize treatment plans.[1]
- **High-Throughput Screening (HTS) Market Growth:** The HTS market is projected for significant growth, driven by the need for efficient and rapid testing of drug compounds. PAOI's capabilities in generating high-quality data for predictive models and supporting biomarker discovery align with this trend.[11]
- **Geographic and Therapeutic Expansion:** The aggressive market expansion of ChemoFx® in the U.S. and Europe, and the anticipation to extend its application beyond gynecological cancers to other tumor types (breast, colon, lung), offers substantial growth potential.[7]
- **Strategic Collaborations (ACE Program):** The success of its ACE program with the University of Michigan and the active call for new submissions indicate opportunities for further collaborative innovation, expanding its research capabilities and validating its platforms.[12]

Threats

- **High Failure Rates in Drug Development:** Despite PAOI's efforts to improve success rates, the broader oncology drug development industry is characterized by high failure rates in clinical trials, which can impact partner pipelines and overall market sentiment.[1]
- **Intense Competition:** The biotechnology and pharmaceutical sectors are highly competitive, with numerous companies developing novel oncology treatments and diagnostic tools. Competitors may emerge with similar or superior AI platforms, biobanks, or assays.
- **Regulatory Hurdles:** The development and commercialization of new oncology

therapies and diagnostic tools are subject to complex and evolving regulatory requirements (e.g., FDA, EMA). Delays or failures in regulatory approvals could significantly impact market entry and revenue.
- **Data Security and Privacy Concerns:** Handling a vast biobank of sensitive patient data carries inherent risks related to data security breaches and privacy regulations, which could lead to legal penalties and reputational damage.
- **Economic Downturns:** Economic instability or reduced investment in R&D by biopharma companies could impact demand for PAOI's services and collaborations.

9. Customer Segmentation & Deep Dive

Predictive Oncology (PAOI) primarily serves the biopharmaceutical industry and the clinical oncology community, addressing critical needs in drug discovery, development, and personalized patient care.

9.1. Biopharmaceutical Partners

- **Segmentation:** This segment includes pharmaceutical companies, biotechnology firms, and contract research organizations (CROs) engaged in oncology drug discovery and development.
- **Needs & Pain Points:**
  - **Reducing Clinical Trial Failure Rates:** Biopharma companies face high failure rates in clinical trials, primarily due to a lack of efficacy against selected targets. They need solutions that can increase the probability of success and reduce the immense costs associated with failed trials.[1]
  - **Optimizing Early Drug Discovery:** There is a critical need to efficiently identify promising drug candidates and effective drug-tumor pairings early in the discovery process to avoid costly late-stage failures.[1]
  - **Addressing Tumor Heterogeneity:** Cancer is highly heterogeneous, and traditional models often fail to capture this complexity. Biopharma partners require tools that can account for patient and tumor diversity to develop more effective and personalized therapies.[1]
  - **Access to Relevant Data and Models:** They seek access to large, diverse biobanks of human tumor samples and advanced *in vitro* models that better mimic the physiological environment for more reliable testing.[1]
  - **Accelerating Development Timelines:** Speed-to-market is crucial in the

competitive drug development landscape. Solutions that can expedite the discovery and validation process are highly valued.

- **PAOI's Value Proposition:** PAOI's AI/ML platform (PeDAL) and extensive biobank directly address these needs by making high-confidence drug-response predictions and enabling more informed selection of drug/tumor type combinations. Its 3D tumor models provide clinically relevant testing, and its integrated CRO services support partners in advancing molecules to medicine with confidence and accuracy.[1]

9.2. Clinicians and Healthcare Providers

- **Segmentation:** This segment includes oncologists, pathologists, and other healthcare professionals involved in cancer diagnosis and treatment.
- **Needs & Pain Points:**
  - **Personalized Treatment Guidance:** Clinicians need tools to individualize treatment plans for cancer patients, moving away from a "trial-and-error" approach to more effective, targeted therapies.[7]
  - **Improved Patient Outcomes:** The ultimate goal is to enhance patient quality of life, extend life, or achieve cures through more precise treatment decisions.[1]
  - **Faster and Better Decision-Making:** Access to rapid and accurate information on how a patient's tumor will respond to specific drugs is crucial for timely and effective interventions.[7]
- **PAOI's Value Proposition:** The ChemoFx® assay provides personalized guidance by measuring chemotherapy responses *in vitro* using a patient's own cells. This enables oncologists to make better and faster treatment decisions, potentially improving patient outcomes and saving time and money.[7] Helomics, a subsidiary, also provides clinical testing services to assist oncologists in individualizing patient treatment decisions.[1]

10. Sales & Distribution Strategy Analysis

Predictive Oncology's sales and distribution strategy is primarily focused on direct engagement with its target customer segments: biopharmaceutical companies and clinical oncology practices, leveraging its scientific expertise and unique technological assets.

10.1. Sales Channels

- **Direct Sales to Biopharma:** PAOI engages directly with pharmaceutical and biotechnology companies to offer its AI-driven drug discovery services, access to its biobank, and collaborative research opportunities. This involves scientific presentations, pilot programs (like the PeDAL Pilot Program), and tailored solutions for specific drug development challenges.[1]
- **Clinical Lab Services (Helomics):** Through its Helomics subsidiary, PAOI provides clinical testing services directly to oncologists and healthcare providers, assisting in personalized treatment decisions. This channel relies on direct relationships with medical professionals and potentially referrals.[1]
- **Channel Partnerships for ChemoFx® Expansion:** For the aggressive market expansion of its ChemoFx® assay in the U.S. and Europe, PAOI is actively engaged in discussions with potential channel partners. These partners could include diagnostic distributors, laboratory networks, or other healthcare service providers that can facilitate broader adoption and reach within the clinical market.[7]
- **Direct Sales of Research Tools (TumorGenesis, Soluble Biotech):** TumorGenesis sells specialized media for growing cancer cells, and Soluble Biotech sells protein solubilization kits. These products are likely distributed directly to researchers, academic institutions, and other biotech companies, potentially through online platforms or scientific sales representatives.[33]

10.2. Go-to-Market (GTM) Strategy

- **Scientific Validation and Data-Driven Approach:** PAOI's GTM strategy heavily emphasizes the scientific validation of its platforms, such as the 92% accuracy of its AI/ML predictions and the clinical relevance of its 3D tumor models. This scientific credibility is crucial for gaining trust and adoption in the highly technical biopharma

and clinical markets.[1]

- **Leveraging Unique Assets:** The company highlights its "world's largest privately held biobank" as a key differentiator, offering unparalleled access to diverse human tumor samples and longitudinal data for drug discovery and validation.[1]
- **Addressing Industry Pain Points:** The GTM messaging directly addresses the high failure rates in traditional oncology drug development, positioning PAOI's solutions as a means to "improve the probability of success" and "advance molecules to medicine with confidence and accuracy."[1]
- **Collaborative Development:** The "Let's discover and develop together" approach, including programs like the ACE program, indicates a GTM strategy focused on collaborative partnerships with biopharma and academic institutions to co-develop solutions and validate technologies.[12]
- **Geographic Expansion:** The planned "de novo Launch in Europe" for ChemoFx® signifies a strategic push into new international markets, likely involving localized marketing and distribution efforts tailored to European regulatory and healthcare landscapes.[7]
- **Content Marketing and Thought Leadership:** The availability of white papers, webinars, and news releases suggests a strategy of thought leadership to educate the market on its innovative approaches and scientific advancements.[12]

11. Operational Efficiency Metrics

Predictive Oncology's operational efficiency is intrinsically linked to its advanced technological platforms and specialized facilities, which are designed to streamline the complex processes of oncology drug discovery and personalized medicine. While specific financial efficiency ratios (e.g., gross margin, operating cash flow margin) are not detailed in the provided research, the operational structure points to key areas of efficiency.

11.1. Key Operational Aspects and Efficiency Drivers

- **CLIA-Certified Lab Operations (Helomics):** Helomics operates a CLIA-certified lab, which is essential for providing clinical testing services. Maintaining this certification requires rigorous quality control and standardized procedures, contributing to operational reliability and accuracy in clinical diagnostics.[1]
- **GMP Facilities (TumorGenesis, Soluble Biotech):** TumorGenesis and Soluble

Biotech are constructing or operating Good Manufacturing Practice (GMP) facilities. GMP compliance ensures high standards of quality control in the production of cancer cell media and protein formulations, which is critical for products used in research and Phase 1 clinical trials. This operational rigor minimizes errors and ensures product consistency.[33]

- **Wet Lab for AI Validation:** The PeDAL team tests AI predictions against actual tumor samples in its on-site wet lab. This integration of computational AI with physical lab validation creates an iterative process that refines predictions and increases confidence, potentially reducing the need for extensive, costly *in vivo* testing later in the development cycle.[12]
- **Biobank Management:** Managing the world's largest privately held biobank of over 150,000 tumor samples and 200,000 pathology slides requires highly efficient storage, retrieval, and data management systems. The ability to efficiently query this biobank and derive rich data is a core operational strength that feeds the AI platform.[1]
- **High-Throughput Screening (HTS) Capabilities:** The company's capabilities in obtaining patient tumor samples and monitoring their growth and drug response in 2D cell culture, cryopreservation, and 3D cell spheroids directly support high-throughput drug discovery. This enables efficient testing of large experimental spaces, which is crucial for accelerating drug development and reducing costs.[11]
- **AI-Driven Optimization:** The core AI/ML platform (PeDAL) itself is an efficiency driver. By making high-confidence drug-response predictions with up to 92% accuracy, it helps optimize early drug discovery efforts, increase the odds of technical success in clinical trials, and enable more efficient drug repurposing. This reduces wasted resources on ineffective compounds.[1]
- **Streamlined Clinical Decision-Making (ChemoFx®):** The ChemoFx® assay aims to eliminate the "trial-and-error" approach in chemotherapy selection, enabling oncologists to make better and faster treatment decisions. This directly translates to operational efficiency in clinical practice by potentially reducing unnecessary treatments and improving patient pathways.[7]

12. Technology & IP Strategy

Predictive Oncology's technology and intellectual property (IP) strategy is central to its business, driven by its proprietary platforms, extensive biobank, and continuous innovation across its product lines, all aimed at revolutionizing oncology drug discovery and personalized medicine.

12.1. Key Technologies and IP Focus

- **Proprietary AI/ML Platform (PeDAL):** The cornerstone of PAOI's IP is its proprietary AI/ML platform, PeDAL. This platform leverages active machine learning and historical drug-response data, combined with first-party data from partners, to make high-confidence predictions of drug-tumor pairings. The iterative process of AI predictions informed by wet-lab testing results is a key technological differentiator, designed to optimize early drug discovery and increase the odds of technical success in clinical trials.[1]
- **Extensive Biobank as a Data Asset:** Predictive Oncology's biobank, described as the world's largest privately held collection of over 150,000 heterogeneous human tumor samples, 200,000 pathology slides, and decades of longitudinal drug response data, is a critical proprietary asset. This rich data source fuels the AI platform and enables deep insights into patient and tumor heterogeneity, which is crucial for developing precision medicines.[1]
- **Advanced 3D Tumor Models:** The company's use of proprietary 3D tumor models is a significant technological advantage. These models are designed to mimic the complex human organ microenvironment, providing a more clinically relevant testing platform than conventional 2D cell cultures, thereby enhancing the predictive power of their assays and models.[1]
- **ChemoFx® Assay Technology:** The ChemoFx® assay is a proprietary live-cell tumor profiling technology. Its ability to measure chemotherapy responses *in vitro* using a patient's own cells provides personalized guidance for treatment selection. This assay is a renewable and extensible asset that also serves as a primary method for augmenting the company's biobank.[7]
- **GMP-Compliant Manufacturing Capabilities:** The GMP facilities operated by subsidiaries like Soluble Biotech and TumorGenesis are integral to PAOI's technological infrastructure. Soluble Biotech's proprietary technology for developing soluble and stable protein formulations and TumorGenesis' specialized media for growing cancer cells under GMP conditions represent key technological capabilities for drug development and research tool provision.[33]
- **Focus on Biomarker Discovery:** The integration of AI with multi-omics and multi-modal data expertise, particularly through the capabilities gained from the proposed Renovaro merger (though terminated, it highlights a strategic interest), indicates a focus on biomarker discovery and diagnostic applications in oncology.

12.2. Innovation Roadmap

Predictive Oncology's innovation roadmap is centered on continuous enhancement of its core platforms and expansion of its clinical applications:

- **Next-Generation ChemoFx® Development:** The company is actively developing the next generation of its ChemoFx® assay, with plans to extend its application beyond gynecological cancers to other tumor types, including breast, colon, and lung. This expansion will broaden its clinical utility and market reach.[7]
- **ACE Program for Collaborative Innovation:** PAOI is actively calling for submissions for its ACE program in 2025, following successful results with the University of Michigan. This program fosters collaborative research, allowing external partners to leverage PAOI's biobank and AI/ML platform for novel drug discovery projects, thereby expanding its innovation ecosystem.[12]
- **Continuous AI/ML Refinement:** The iterative process of AI predictions and wet-lab validation suggests an ongoing commitment to refining its machine learning algorithms and predictive models, ensuring they remain at the forefront of oncology drug discovery.[12]
- **Leveraging Biobank for New Insights:** The company continues to explore new ways to leverage the rich data from its biobank to gain deeper insights into patient heterogeneity and drug response, driving future innovations in personalized medicine.[1]

13. Risk Heatmap

Predictive Oncology operates within the highly complex and regulated biotechnology and pharmaceutical sectors, which inherently carry various risks. Based on its business model, recent corporate activities, and the broader industry landscape, the following potential risks can be identified:

Risk Category	Level of Risk	Key Contributing Factors
Technological and Scientific Risk	High	Reliance on proprietary AI/ML platforms and 3D tumor models means that any failure in the accuracy or scalability of

		these technologies could significantly impact product efficacy and market adoption. The success of drug discovery is inherently uncertain, with high failure rates in clinical trials.[3]
Clinical and Regulatory Risk	High	As a company involved in drug discovery and clinical testing, PAOI is subject to stringent regulatory oversight (e.g., FDA, CLIA). Changes in regulations, delays in approvals, or failure to meet compliance standards could impede product development and market expansion. The ChemoFx® assay's market expansion is subject to regulatory pathways in the U.S. and Europe.[7]
Market Adoption and Competition Risk	Medium to High	The oncology and drug discovery market is highly competitive. Adoption of PAOI's AI-driven solutions and assays like ChemoFx® depends on demonstrating clear advantages over existing methods. Competitors may develop superior technologies or offer more cost-effective solutions.
Financial and Funding Risk	Medium	As a company engaged in long-term R&D and drug development, sustained funding is crucial. While the company has secured financing tranches, the ability to secure future capital for ongoing research, clinical trials, and market expansion remains a consideration.

Intellectual Property (IP) Risk	Medium	Protecting its proprietary AI algorithms, biobank data, and assay technologies (e.g., ChemoFx®) is critical. Challenges to patents, unauthorized use of proprietary data, or the inability to secure new IP could undermine its competitive advantage.
Partnership and Collaboration Risk	Medium	PAOI collaborates with biopharma partners. The success of these collaborations depends on mutual objectives and execution. The termination of the proposed merger with Renovaro Biosciences, and the ensuing legal dispute, highlights the risks associated with strategic partnerships not reaching fruition.[20]
Data Security and Privacy Risk	Medium	Managing a vast biobank of patient tumor samples and associated longitudinal data necessitates robust data security and privacy protocols. Breaches could lead to significant legal, financial, and reputational damage.

14. Strategic Recommendations

Predictive Oncology's strategic direction should focus on leveraging its unique technological assets and market position to drive growth and mitigate inherent industry risks.

- **Accelerate AI/ML Platform and Biobank Integration:** Continue to invest heavily in enhancing the PeDAL platform and expanding the utility of the biobank. This includes further validating the 92% prediction accuracy and exploring new applications for its extensive data set to solidify its position as a leader in AI-driven

precision oncology.[1]

- **Aggressive Market Expansion for ChemoFx®:** Prioritize and execute the aggressive market expansion strategy for the ChemoFx® assay in the U.S. and Europe. This involves securing key channel partnerships and extending the assay's application beyond gynecological cancers to other tumor types like breast, colon, and lung, thereby broadening its revenue streams and clinical impact.[7]
- **Strategic Partnerships and Collaborations:** Actively seek and cultivate strategic partnerships with biopharma companies, academic institutions, and other key players in the oncology ecosystem. These collaborations can provide additional funding, expand research capabilities, and accelerate the translation of discoveries into clinical applications, while carefully managing the risks associated with such alliances.[1]
- **Continuous Innovation in 3D Tumor Models:** Further develop and integrate advanced 3D tumor models to provide even more physiologically relevant testing platforms. This will enhance the predictive power of PAOI's assays and models, increasing confidence in drug efficacy predictions and reducing reliance on less accurate traditional models.[1]
- **Robust Intellectual Property Protection:** Maintain a proactive and comprehensive strategy for protecting its intellectual property, including patents, trade secrets, and proprietary data. This is crucial for safeguarding its technological innovations and competitive advantage in a rapidly evolving field.

15. Market Trends & Strategic Outlook, and CEO Strategic Supplement

15.1. Market Trends & Strategic Outlook

The strategic outlook for Predictive Oncology is shaped by several significant trends in the healthcare and biotechnology sectors, particularly within oncology:

- **Growth of AI in Drug Discovery:** The increasing adoption of artificial intelligence and machine learning is revolutionizing drug discovery, offering unprecedented capabilities to analyze complex biological data, predict drug responses, and accelerate development timelines. PAOI is well-positioned to capitalize on this trend with its proprietary AI/ML platforms.[1]
- **Rise of Precision and Personalized Medicine:** There is a strong global shift towards personalized medicine, where treatments are tailored to individual patient

profiles. PAOI's focus on individualizing cancer therapies through tumor drug-response testing and genomic biomarker profiling aligns directly with this growing demand.[1]

- **Increasing Demand for High-Throughput Screening (HTS):** The high-throughput screening market is projected to reach $69.5 billion by 2032, reflecting a CAGR of 12.18%, driven by the need for efficient and rapid testing of drug compounds. PAOI's capabilities in generating high-quality data for predictive models and supporting biomarker discovery directly contribute to this market.[11]
- **Adoption of Advanced *In Vitro* Models:** The growing adoption of 3D cell cultures, which provide more physiologically relevant models for drug screening, enhances the predictive power of assays. PAOI's use of 3D tumor models positions it favorably within this trend.[1]
- **Focus on Reducing Clinical Trial Failure Rates:** The high failure rate of traditional clinical trials due to lack of efficacy drives demand for innovative solutions that can improve the probability of success. PAOI's AI-driven approach and biobank are designed to address this critical industry challenge.[1]

Predictive Oncology's strategic outlook is positive, aiming to leverage these trends to expand its market presence and impact. The company anticipates extending its ChemoFx® assay beyond gynecological cancers into other tumor types, indicating a clear path for growth and broader application of its core technologies.[7]

15.2. CEO Strategic Supplement

While specific direct quotes for a CEO Strategic Supplement are not available in the provided research material, the company's public statements and mission reflect a clear strategic vision. The leadership of Predictive Oncology is focused on:

- **Revolutionizing Oncology Drug Discovery:** A core tenet is to change the landscape of oncology drug discovery and enable the development of more effective therapies for the treatment of cancer by integrating scientific rigor with machine learning.[1]
- **Bringing the Human Element Earlier:** The strategy emphasizes introducing human diversity into the discovery process at an earlier stage, primarily through its extensive biobank and 3D tumor models, to better address tumor heterogeneity and improve drug efficacy predictions.[1]
- **Advancing Molecules to Medicine with Confidence:** The company aims to provide biopharma partners with solutions that advance drug compounds with a higher degree of confidence and accuracy, ultimately benefiting cancer patients by enabling more effective therapies.[1]

- **Expanding Clinical Applications:** The continued development and aggressive market expansion of the ChemoFx® assay, with plans to extend its use to various cancer types, underscores a commitment to translating its technology into direct clinical impact and personalized treatment guidance.[7]
- **Fostering Collaboration and Innovation:** The company actively seeks collaborations, as evidenced by its ACE program, to drive innovation and expand its capabilities in AI-driven drug discovery.[33]

Works cited

1. Predictive Oncology: Home, accessed July 22, 2025, https://predictive-oncology.com/
2. About us - Predictive Oncology, accessed July 22, 2025, https://predictive-oncology.com/about-us/
3. Leadership Team - Predictive Oncology, accessed July 22, 2025, https://predictive-oncology.com/basic-facts/leadership-team/
4. Predictive Oncology Moves to Finalize Definitive Merger Agreement With Renovaro Biosciences, accessed July 22, 2025, https://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-moves-finalize-definitive-merger-agreement
5. SEC Filings | Predictive Oncology, accessed July 22, 2025, https://investors.predictive-oncology.com/financial-information/sec-filings
6. Predictive Oncology Inc. Common Stock (POAI) SEC Filings - Nasdaq, accessed July 22, 2025, https://www.nasdaq.com/market-activity/stocks/poai/sec-filings
7. Predictive Oncology Issues Shareholder Letter: Well Financed to Support Expanded U.S. Availability and E.U. Launch of ChemoFx® and Pursuit of Other High-Value AI-Driven Drug Discovery and Development Opportunities - GlobeNewswire, accessed July 22, 2025, https://www.globenewswire.com/news-release/2025/07/15/3115649/37244/en/Predictive-Oncology-Issues-Shareholder-Letter-Well-Financed-to-Support-Expanded-U-S-Availability-and-E-U-Launch-of-ChemoFx-and-Pursuit-of-Other-High-Value-AI-Driven-Drug-Discovery-.html
8. Predictive Oncology Completes Acquisition of Soluble Therapeutics and BioDtech, accessed July 22, 2025, https://www.biospace.com/predictive-oncology-completes-acquisition-of-soluble-therapeutics-and-biodtech
9. Drug Discovery - Scientists - Predictive Oncology, accessed July 22, 2025, https://predictive-oncology.com/everytumor/
10. Predictive Oncology Inc.'s Subsidiaries Soluble Biotech Inc. and TumorGenesis Inc. are both constructing new GMP labs - BioSpace, accessed July 22, 2025, https://www.biospace.com/predictive-oncology-inc-s-subsidiaries-soluble-biotech-inc-and-tumorgenesis-inc-are-both-constructing-new-gmp-labs
11. Predictive Oncology Inc.'s Subsidiaries Soluble Biotech - GlobeNewswire, accessed July 22, 2025, https://www.globenewswire.com/news-release/2021/06/22/2250989/0/en/Predictive-Oncology-Inc-s-Subsidiaries-Soluble-Biotech-Inc-and-TumorGenesis-Inc-are-both-constructing-new-GMP-labs.html
12. Predictive Oncology Completes Acquisition of Soluble Therapeutics and BioDtech, accessed July 22, 2025, https://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-completes-acquisition-soluble-therapeutics
13. predictive oncology inc. - SEC.gov, accessed July 22, 2025, https://www.sec.gov/Archives/edgar/data/1446159/000117184319008282/f424b3_122019.htm
14. Predictive Oncology - SEC.gov, accessed July 22, 2025, https://www.sec.gov/Archives/edgar/data/1446159/000117184319006929/s1_102

919.htm
15. Predictive Oncology Inc.'s Wholly Owned Subsidiary, TumorGenesis, Partners with Cellevate AB, accessed July 22, 2025, https://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-incs-wholly-owned-subsidiary-tumorgenesis
16. Alabama Company Improves the Delivery of Protein Therapies - NIH's Seed, accessed July 22, 2025, https://seed.nih.gov/sites/default/files/2022-10/soluble-bio.pdf
17. Alabama Company Improves the Delivery of Protein Therapies - NIH's Seed, accessed July 22, 2025, https://seed.nih.gov/portfolio/stories/Soluble-Biotech
18. Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology - GlobeNewswire, accessed July 22, 2025, https://www.globenewswire.com/news-release/2025/03/03/3035729/0/en/Renovaro-Completes-First-Milestone-Payment-to-Finalize-Definitive-Agreement-with-Predictive-Oncology.html
19. poai20250718_8k.htm - SEC.gov, accessed July 22, 2025, https://www.sec.gov/Archives/edgar/data/1446159/000117184325004558/poai20250715_8k.htm
20. Renovaro Provides Update to Definitive Agreement with Predictive Oncology - Stock Titan, accessed July 22, 2025, https://www.stocktitan.net/news/RENB/renovaro-provides-update-to-definitive-agreement-with-predictive-82yco5dstz0x.html
21. DeRoyal Industries 2025 Company Profile: Valuation, Investors, Acquisition | PitchBook, accessed July 22, 2025, https://pitchbook.com/profiles/company/265309-12
22. company overview, accessed July 22, 2025, https://www.deroyal.com/docs/default-source/web-branding/deroyal-corporate-overview/deroyal_company_overview_2023.pdf?sfvrsn=151b2b20_84
23. Predictive Oncology has Announced Agreement to be Acquired by Renovaro - OncoDaily, accessed July 22, 2025, https://oncodaily.com/insight/predictive-oncology-219281
24. Renovaro to Acquire Predictive Oncology in All-Stock Transaction - Investor Relations, accessed July 22, 2025, https://ir.renovarogroup.com/news/news-details/2025/Renovaroto-Acquire-Predictive-Oncology-in-All-Stock-Transaction/default.aspx
25. Predictive Oncology Announces Agreement to be Acquired by Renovaro, accessed July 22, 2025, https://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-announces-agreement-be-acquired-renovaro
26. Renovaro (RENB) Company Profile & Description - Stock Analysis, accessed July 22, 2025, https://stockanalysis.com/stocks/renb/company/
27. About - Renovaro Biosciences, accessed July 22, 2025, https://renovarocube.com/about/
28. BioSymetrics Company Profile - Office Locations, Competitors, accessed July 22, 2025, https://craft.co/biosymetrics
29. BioSymetrics - Phenomics-Driven. Remote-First., accessed July 22, 2025, https://www.biosymetrics.com/
30. Predictive Oncology to Finalize Merger Agreement With Renovaro Biosciences,

accessed July 22, 2025, https://www.americanpharmaceuticalreview.com/1315-News/618012-Predictive-Oncology-to-Finalize-Merger-Agreement-With-Renovaro-Biosciences/
31. Growth or Bubble? Decoding POAI's Sudden Surge - StocksToTrade, accessed July 22, 2025, https://stockstotrade.com/news/predictive-oncology-inc-poai-news-2025_03_25/
32. ir.renovarogroup.com, accessed July 22, 2025, https://ir.renovarogroup.com/news/news-details/2025/Renovaro-Completes-First-Milestone-Payment-to-Finalize-Definitive-Agreement-with-Predictive-Oncology/default.aspx#:~:text=Renovaro%20Completes%20First%20Milestone%20Payment%20to%20Finalize%20Definitive%20Agreement%20with%20Predictive%20Oncology,-March%203%2C%202025&text=LOS%20ANGELES%2C%20March%2003%2C%202025,NEWSWIRE)%20%2D%2D%20Renovaro%20Biosciences%20Inc.
33. Helomics - Predictive Oncology, accessed July 22, 2025, https://predictive-oncology.com/our-companies/helomics/

Introduction to the Publisher
C2C Business Strategies Financial Publishing & Research Group:

C2C Business Strategies actively monitors hundreds of lower middle market companies. This includes privately held companies and publicly traded companies across NYSE, NASDAQ, and OTC Markets. Through periodic Strategic Financial & Operational Analysis Reports, we highlight emerging opportunities—while also identifying material risks that could impact performance, valuation, or investor confidence. These insights help stakeholders better understand both the upside potential and the structural vulnerabilities of public micro- and small-cap enterprises.

We specialize in comprehensive financial reports for public and private lower middle market companies, providing detailed, customized financial analysis and reporting for businesses typically generating between $5 million and $50 million in annual revenue. These companies occupy a unique space: larger than small businesses, yet not quite large corporations. They often face distinct financial challenges and opportunities. For public companies in this segment, financial reporting must meet strict regulatory standards, ensuring transparency and accuracy for stakeholders and regulators. Private companies, while not subject to the same public scrutiny, still require robust financial reports to inform management decisions, attract investors, and support growth strategies. By focusing on the lower middle market, our expertise ensures that both public and private companies receive the high-quality, actionable financial insights needed to drive performance, maintain compliance, and achieve their strategic goals.